Chronos Archive seal

Review checklist: Johnny Cash (HR-ML004)

All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments

Everything a reviewer needs to judge, gathered from the record. Release status: draft.

Review status

ReviewStatusReviewerDateNotes
schema validationnot_startedRun scripts/build.ps1 -Conformance.
clinical reviewnot_startedAwaiting clinician review.
provenance reviewnot_startedRecent-death rule: only facts Cash, his manager, or published reference works made public are used. Encyclopedia of Arkansas, ABC News, CNN transcript, and Pollstar logged.
safe messaging reviewnot_startedHistorical substance use is recorded as history, marked sensitive, and is not a modern diagnosis. Death recorded without graphic detail.

Judgment calls (dossier editorial resolutions)

  1. Recent-death rule. Cash died in 2003. The case uses only what Cash himself, his manager, and published reference works made public: his own televised statements, the hospital-issued statement at his death, a news report, and an encyclopedia entry. No medical records, family accounts beyond those sources, or speculation about undisclosed conditions are used. The recent-death review rule applies.
  2. Index age. The modern episode presents Cash at 71, a few months after the November 2002 interview in which he described his diabetes, neuropathy, glaucoma, and vision loss, so the clinical notes can cite what he made public. Age 70, his age at the interview, would have put the true-date visits before the interview (the visit window ends on November 1, 2026). The synthetic date of birth is February 26, 1955 (shift 23 years); the index visit on February 27, 2026 maps to February 27, 2003, and the last visit on August 14, 2026 maps to August 14, 2003, before his final hospitalization and death. The annual wellness visit on April 24, 2026 (true frame April 24, 2003) sits between the existing visits. Past medical history and family history include only events before the index date. The episode does not mention June Carter Cash, who died on May 15, 2003, during the true-date span of the visits; the supports are described generically.
  3. Diabetes. His diabetes is documented by his own statement and by his manager’s statement at his death. When it was diagnosed and how it was treated were not found in the sources and are not recorded. The modern diagnosis, HbA1c values, and medicines are synthetic.
  4. Shy-Drager syndrome. The October 1997 diagnosis and Cash’s later statement that it was wrong are both documented (D). The teaching episode treats his autonomic symptoms as diabetic autonomic neuropathy, which is consistent with what he made public, and does not put Shy-Drager syndrome or multiple system atrophy on the problem list. The CNN rush transcript dates his undiagnosed illness to 1993 and orders the diagnoses differently; the case uses the October 1997 date reported by ABC News and does not record the transcript’s sequence.
  5. Glaucoma. Cash mentioned “the glaucoma” on air but did not give its type or stage, so the claim is graded D with certainty probable. Primary open-angle glaucoma, severe stage, and the mild diabetic retinopathy are synthetic choices.
  6. Substance use. His amphetamine and barbiturate use and his treatment at the Betty Ford Clinic are well documented and were made public by Cash. They are recorded as history, marked sensitive, and kept off the problem list. The modern social history records them only to guide prescribing (avoiding controlled stimulants and sedatives). No behavioral-health diagnosis is coded, so no safety assessment is required.
  7. Annual wellness visit. A subsequent Medicare annual wellness visit was added on April 24, 2026 (true frame April 24, 2003), four weeks after the endocrinology consultation and five weeks before the three-month review. The true-frame visits fall in his last months, so the visit was placed between existing visits rather than after the schedule, and well before his documented final hospitalization. No sick visit was added: under the recent-death rule the case adds no synthetic illness episode, and his documented pneumonia admissions are not echoed with a synthetic infection. Judgment calls: (1) the visit records no new diagnosis, fall, or hospital stay, and the safety-events history covers only the time since his first visit, not the preceding year, so it does not contradict his documented admissions; (2) the eye examination is recorded as current because the dilated examination at the first visit also served as diabetic retinopathy screening, with glaucoma care left with the eye clinic; (3) the AUDIT-C (score 0) is administered as a routine screen like any other, the past substance use is not restated in the note, and the prescribing precautions stay in the social history only; hepatitis C screening is offered as the universal one-time screen for adults through 79, not because of his history; (4) cognition is assessed by direct observation, and the Mini-Cog from two months earlier is not repeated; (5) lung cancer and aneurysm screening are marked not indicated because the record's social history records no tobacco use; the case makes no further claim about his smoking history; (6) advance care planning records his stated priorities, drawn from the existing health concerns (keeping his sight, staying at home, continuing to write), and an unnamed health care agent, but deliberately records no preference about life support or resuscitation, because the true-frame date is months before his documented final hospitalization and such a preference could read as a claim about his real end-of-life choices; (7) the family member who helps at home stays generic, consistent with the decision to omit June Carter Cash; (8) the FIT kit and hepatitis C test are ordered but no results are recorded, and the first zoster dose is planned for the three-month review, where it is already recorded.
  8. Focused visits. The three chronic-care follow-ups (the endocrinology consultation four weeks after intake, the three-month review, and the six-month review) are documented as focused visits on the CMID diabetes, glaucoma, and hyperlipidemia monographs, and each lists every item those protocols call for at that point, with its interval and status. Synthetic details introduced, all consistent with the existing record: home glucose ranges with no reading below 70 mg/dL; lying, seated, and standing blood pressures at each visit (the seated values and the six-month standing value of 120/70 are the recorded ones; the lying values stay below 150 mmHg, so there is no supine hypertension on midodrine); smaller lunches for the fall in pressure after meals; physical therapy and the low-vision home visit carried out after the wellness-visit referrals, including the second stair handrail; and a 24-2 visual field and optic nerve appearance unchanged from intake. The neurogenic cause of the orthostatic hypotension is shown from the recorded intake values (a 34 mmHg fall with a rise of 4 beats per minute) and the four-week values; the endocrinology note says only that the earlier Shy-Drager label is not carried forward, and adds no examination finding about parkinsonism, consistent with the decision not to use the Parkinson’s disease announcement. Protocol deviations recorded instead of invented results: (1) no eye pressure check four to six weeks after dorzolamide was added, judged harmless at six months because OCT, acuity, and fields were stable; (2) the post-statin lipid panel drawn at 13 weeks, one week outside the 4-to-12-week window; (3) no FIB-4 at intake because no platelet count was drawn; (4) lipoprotein(a) not yet measured; (5) no 10-2 visual field in severe glaucoma; and (6) no diabetes self-management education in the first six months, with a referral at the six-month review. Annual items not yet done (diabetes distress, anxiety, disordered eating, social needs, dental examination, vitamin B12 recheck) are marked due. The hepatitis C antibody planned at the wellness visit is recorded as drawn at the three-month review, and at six months its result is recorded as not on file and requested, so no result is invented; the FIT kit is recorded as not yet returned. The recent-death rule is kept: no new illness, symptom, or finding is added, and no relative appears in the notes.
  9. Consultation. The endocrinology referral and Dr. Rahimi's consultation, seen on the same day as the four-week diabetes check, are synthetic and are written to agree with the record: midodrine and sitagliptin started that day, the later increase to midodrine 5 mg, and the HbA1c course. The consultation uses only the recorded history, examination, and results; the referral raises the publicly described Shy-Drager label only to ask whether it should be carried forward, and the note adds no examination finding about parkinsonism and no new symptom or diagnosis. No relative is named; the patient alone agrees to the plan. Judgment calls: (1) formal autonomic testing is judged unnecessary because it would not change treatment; (2) GLP-1 receptor agonists and SGLT2 inhibitors are passed over for tolerability with autonomic neuropathy and orthostatic hypotension, without stating that he has early fullness (the same-day review of systems records none); (3) diabetes self-management education is not part of the consultation, so the deviation recorded at six months stands as written.
  10. Not used. The family’s and biographers’ accounts of his final weeks, the Parkinson’s disease announcement at the October 1997 Flint concert, reports of asthma, and the dates of his parents’ deaths were not verified in a fetched source and are not recorded. The 1983 internal bleeding is recorded without a cause because the source gives none.

Protocol deviations

Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.

VisitMeasureIntervalWhat happened
2026-03-27
Progress note 02 (C-CDA)
Tonometry (eye pressure)Every glaucoma visit; 4 to 6 weeks after adding a dropNot measured at this visit, and no eye-clinic check has been booked since dorzolamide was added four weeks ago, a deviation from the plan. Request sent to the eye clinic
2026-05-29
Progress note 04 (C-CDA)
ALT, AST, and platelets for FIB-4At diagnosis and yearlyFIB-4 could not be calculated at intake because no platelet count was drawn with the hemoglobin, a deviation from the protocol. ALT and AST were normal at intake and ALT is normal today, so missed liver scarring is unlikely; AST and a platelet count are added to the annual tests
2026-05-29
Progress note 04 (C-CDA)
Lipoprotein(a)Once in adulthoodNot yet measured, a deviation from the protocol. It would not change treatment now, since he already takes a high-intensity statin; added to the annual lipid panel
2026-08-14
Progress note 05 (C-CDA)
Visual field (Humphrey 10-2)In advanced disease, alongside the 24-2Not done at intake or today, a deviation from the protocol for severe glaucoma. The 24-2 and OCT are stable, so loss near fixation is unlikely to have been missed; the eye clinic will add a 10-2 at the next field visit

Orders and referrals without results in the record

VisitTypeItemStatusDetail
2026-04-24
Progress note 03 (C-CDA)
PreventionFalls preventionReferredPhysical therapy for gait and balance and low-vision rehabilitation for home safety
2026-04-24
Progress note 03 (C-CDA)
PreventionColorectal cancer screeningOrderedNo screening result on file; stool FIT kit given, to be returned by mail
2026-04-24
Progress note 03 (C-CDA)
PreventionHepatitis C screeningOrderedOne-time screening recommended for all adults through age 79; added to the three-month laboratory tests
2026-08-14
Progress note 05 (C-CDA)
ReferralDiabetes self-management education and medical nutrition therapyReferredNot arranged in the first six months despite two medication changes, a deviation from the protocol. No harm resulted, since HbA1c reached goal without hypoglycemia. Referred today to an individual program with large-print materials because of his vision

Evidence to check

Retrospective claims (R)

None.

Sensitive claims

ClaimGradeStatement
CLM-0004DIn 1957 Cash began taking amphetamines to stay awake on a long road trip, the start of an addiction that lasted about a decade; in a 2002 interview he named amphetamines and barbiturates in the 1960s.
CLM-0005DCash was hospitalized in 1983 with internal bleeding; after recovering he entered the Betty Ford Clinic for treatment.

Diagnoses not confirmed

None.

Notes to read

Every note in the record, with its type. All clinical content is synthetic.

Abnormal results

DateResultValueFlag
2026-02-27HbA1c8.6% (high)High
2026-02-27Glucose186 mg/dL (high)High
2026-02-27LDL cholesterol128 mg/dL (high)High
2026-02-27Intraocular pressure, right eye22 mmHg (high)High
2026-02-27Intraocular pressure, left eye24 mmHg (high)High
2026-02-27Mean RNFL thickness by OCT, right eye61 um (low)Low
2026-02-27Mean RNFL thickness by OCT, left eye57 um (low)Low
2026-02-27Best-corrected visual acuity, right eye (ETDRS letters)68 (low)Low
2026-02-27Best-corrected visual acuity, left eye (ETDRS letters)63 (low)Low
2026-03-27Glucose152 mg/dL (high)High
2026-05-29HbA1c7.7% (high)High
2026-08-14HbA1c7.3% (high)High
2026-08-14Glucose131 mg/dL (high)High
2026-08-14Mean RNFL thickness by OCT, right eye60 um (low)Low
2026-08-14Mean RNFL thickness by OCT, left eye57 um (low)Low
2026-08-14Best-corrected visual acuity, right eye (ETDRS letters)68 (low)Low
2026-08-14Best-corrected visual acuity, left eye (ETDRS letters)62 (low)Low